The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGooch & Housego Regulatory News (GHH)

Share Price Information for Gooch & Housego (GHH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 550.00
Bid: 548.00
Ask: 558.00
Change: -8.00 (-1.43%)
Spread: 10.00 (1.825%)
Open: 540.00
High: 556.00
Low: 530.00
Prev. Close: 558.00
GHH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Full Year Trading Update

3 Oct 2023 07:00

RNS Number : 4379O
Gooch & Housego PLC
03 October 2023
 

 

 

3 October 2023

 

Gooch & Housego PLC

("G&H" or the "Company" or the "Group")

 

Full Year Trading Update

and

Notice of Results

 

"Trading ahead of expectations. Integration of the two recent acquisitions progressing well"

 

 

Gooch & Housego PLC (AIM: GHH), the specialist manufacturer of photonic components & systems, announces that trading in the second half of the financial year has been strong, continuing the positive trends reported in its interim results. Revenues for the financial year have marginally exceeded market expectations.

 

Trading Update

 

Following the positive performance in the first half, the Group is pleased to report that trading momentum was sustained during the second half of the year.

 

In our Industrial markets volumes of our fibre and acousto optic assemblies used in advanced lithography systems grew more than offsetting the effects of some de-stocking by our customers in our industrial laser markets. Demand for our hi reliability fibre couplers used in subsea data cables has been stable and we expect demand to increase in the new financial year as our customers' new infrastructure projects are delivered.

 

In our A&D business we saw a number of fibre optic assembly programmes transition into full scale production. In the second half of the year, we made good progress on design and development activities for a number of customers for our embedded imaging periscope systems which has the potential to unlock significant orders based upon forecast vehicle build rates. In the commercial aerospace market there is sustained recovery in demand for our ring laser gyro components and we are steadily adding capacity to meet our customers' increased needs.

 

Revenues in the second half the year for our medical diagnostic devices grew thanks to deliveries for new customer programmes commencing. Our engineering team in Ashford is fully utilised supporting our customers new instrument development and qualification programmes.

 

In light of the positive trading performance in H2, enhanced by the focused operational improvements and capability investment over the last year, the Board expects the strong revenue performance to translate into a full year adjusted pre-tax profit above the current market expectations.

 

Acquisitions Update

The integration of GS Optics and Artemis into the G&H Group is proceeding to plan. Our ITL US business, focused on medical diagnostic devices, has now been relocated to GS Optics' facility in Rochester, NY and our expansion programme at that site is underway. We are adding new team members to our manufacturing and engineering teams there to support our US Life Sciences expansion plans as outlined in our new strategy.

The exploitation of commercial synergies between the newly acquired Artemis business and the rest of the G&H Group is already underway with a number of combined optical substrate and coating offerings now available to customers.

Cash

Cash generation in the second half of the financial year has been strong and allowing the Group to reduce its borrowing by $5.5m from its level immediately following the completion of the two acquisitions. Net debt (pre-IFRS 16) at the financial year end is, therefore, expected to be slightly better than market expectations.

Outlook

 

As at 30 September 2023 the Group's order book stood at £124.9m (30 September 2022: £147.7 million and 31 March 2023: £124.4m). Following the normalisation of the order book in the first half of the financial year there was a small order book decline in the second half of around 2.5% when measured on an organic, constant currency basis. Whilst destocking in some parts of our Industrial market is expected to impact in FY2024, especially in the first half, our A&D and Life Sciences revenues are both expected to grow. Around 75% of the order book is for delivery in FY2024 and this provides a good underpin for trading in the new financial year.

Notice of Results

The Company will announce its audited results for the year ended 30 September 2023 on 5 December 2023.

 

Charlie Peppiatt, Chief Executive Officer of Gooch and Housego, commented:

"I am delighted with the positive progress the Group has made in FY2023. Our operational performance has shown sustained improvement with on time delivery and lead times both improving significantly.

"The integration of GS Optics and Artemis into the G&H Group is on track. Both businesses are already benefitting from the additional market access and investment that being part of G&H brings.

"The detailed activities supporting the delivery of our recently announced strategic plan are now in place and support our budgeted plans for FY2024."

 

 

For further information please contact:

 

Charlie Peppiatt, Chief Executive Officer

Chris Jewell, Chief Financial Officer 

Gooch & Housego PLC

+44 (0) 1460 256440

 

Mark Court / Sophie Wills / Abigail Gilchrist

G&H@buchanan.uk.com

Buchanan

+44 (0) 20 7466 5000

 

Christopher Baird / David Anderson

Investec Bank plc

+44 (0) 20 7597 5970

 

 

Notes to editors

 

1.    Gooch & Housego is a photonics technology business headquartered in Ilminster, Somerset, UK with operations in the USA and Europe. A world leader in its field, the company researches, designs, engineers and manufactures advanced photonic systems, components and instrumentation for applications in the Aerospace & Defence, Industrial, Life Sciences and Scientific Research sectors. World leading design, development and manufacturing expertise is offered across a broad range of complementary technologies.

 

2.    All financial information included in this announcement is sourced from unaudited management accounts and excludes any specific items. This announcement contains certain forward-looking statements that are based on management's current expectations or beliefs as well as assumptions about future events. These are subject to risk factors associated with, amongst other things, the economic and business circumstances occurring from time to time in the countries and sectors in which G&H operates. It is believed that the expectations reflected in these statements are reasonable but they may be affected by a wide range of variables which could cause actual results, and G&H's plans and objectives, to differ materially from those currently anticipated or implied in the forward-looking statements. Investors should not place undue reliance on any such statements. Nothing in this announcement should be construed as a profit forecast.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFSFFMEEDSEIS
Date   Source Headline
4th Apr 20247:00 amRNSHalf Year Trading Update
18th Mar 20242:36 pmRNSDivestment of EM4
29th Feb 20247:00 amRNSDirector/PDMR Shareholding
27th Feb 20243:26 pmRNSNotification of Major Holdings
22nd Feb 20244:07 pmRNSNotification of Major Holdings
21st Feb 202412:31 pmRNSResult of AGM
21st Feb 202410:28 amRNSDirector/PDMR Shareholding
21st Feb 20249:43 amRNSDirector/PDMR Shareholding
21st Feb 20247:00 amRNSAGM Trading Update
12th Jan 20247:00 amRNSAnnual Report and Notice of AGM
10th Jan 20247:00 amRNSGrant of LTIP Awards
9th Jan 202411:53 amRNSNotification of Major Holdings
8th Jan 20243:57 pmRNSNotification of Major Holdings
4th Jan 20243:20 pmRNSDirector/PDMR Shareholding
5th Dec 20237:00 amRNSResults for the year ended 30 September 2023
8th Nov 20237:00 amRNSNotification of Full Year Results
23rd Oct 20232:23 pmRNSHolding(s) in Company
3rd Oct 20237:00 amRNSFull Year Trading Update
2nd Oct 20232:44 pmRNSHolding(s) in Company
9th Aug 20236:15 pmRNSDirector/PDMR Shareholding
31st Jul 20238:22 amRNSHolding(s) in Company
21st Jul 202311:58 amRNSCompletion of Acquisition and Issue of Equity
19th Jul 20237:00 amRNSAcquisition of Artemis Optical
23rd Jun 20234:11 pmRNSHolding(s) in Company
21st Jun 202310:26 amRNSDirector/PDMR Shareholding
20th Jun 20236:00 pmRNSAcquisition of GS Optics
6th Jun 20237:00 amRNSInterim Results
23rd May 20237:00 amRNSNotification of Half Year Results
3rd May 20238:56 amRNSIssue of Equity
4th Apr 20237:00 amRNSHalf Year Trading Update
30th Mar 20239:33 amRNSHolding(s) in Company
15th Mar 202312:00 pmRNSAppointment of Non-Executive Director
3rd Mar 20234:37 pmRNSHolding(s) in Company
2nd Mar 20231:10 pmRNSHolding(s) in Company
1st Mar 20239:44 amRNSHolding(s) in Company
22nd Feb 20231:50 pmRNSResult of AGM
22nd Feb 20237:00 amRNSAGM Trading Update
8th Feb 202312:59 pmRNSHolding(s) in Company
9th Jan 202311:44 amRNSGrant of LTIP Awards
21st Dec 202210:02 amRNSPosting of Annual Report and Notice of AGM
20th Dec 202212:30 pmRNSDirector/PDMR Shareholding
6th Dec 20224:26 pmRNSDirector/PDMR Shareholding
6th Dec 20229:38 amRNSDirector/PDMR Shareholding
6th Dec 20227:00 amRNSResults for the year ended 30 September 2022
25th Nov 20223:17 pmRNSHolding(s) in Company
23rd Nov 20224:27 pmRNSHolding(s) in Company
18th Nov 20222:20 pmRNSHolding(s) in Company
2nd Nov 20227:00 amRNSNotification of Full Year Results
27th Oct 202212:56 pmRNSHolding(s) in Company
18th Oct 20222:50 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.